Gallbladder disease: GLP-1-based medications, particularly those approved for weight management, carry an increased risk of gallbladder disease, including gallstones and cholecystitis
Exploratory BMI plots did not reproduce the exenatide subgroup pattern, though this population could not establish that the effect was independent of BMI
New research, however, reveals the potential for additional benefits of the drugs
Some people actually prefer this steadier exposure because it produces more consistent appetite suppression without the "wearing off" feeling that some experience toward the end of their injection week
In addition, activation of T cells in the context of Th1-polarizing and Th17-polarizing requirements with the GLP-1RA liraglutide led to reduced differentiation of Th1 and Th17 cells, while there was no observable change in the number of Tregs [145]